Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrasimod PK with Tasso Device in Healthy Adults
NCT06140290Phase 1Completed
- Sponsor
- Pfizer
- Start
- Dec 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of etrasimod in ulcerative colitis (UC), sponsored by Pfizer. Primary endpoints: Area Under the Serum Concentration-Time Profile From Time Zero to 24 Hours, Area Under the Serum Concentration-Time Profile From Time 24 Hours to the Time of the Last Quantifiable Concentration and 2 more. Started Dec 2023; status: completed.
02
Drugs
etrasimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06140290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06140290.